Latest News & Features
Big Pharma
The Court of Justice of the European Union has rejected two appeals that would have restricted the European Medicines Agency’s right to publish a pharmaceutical company’s clinical trial data, as it relates to their applications to market their products within the EU. 24 January 2020
Big Pharma
Molecular testing company Ascenda BioSciences is suing a former chief operations officer, claiming he attempted to “extort” the return of sensitive company information before taking up employment with a direct competitor. 23 January 2020
Americas
Washington State University is suing two apple producers who it says have infringed its patent through the unlicensed cultivation and sale of a proprietary apple variety. 23 January 2020
Big Pharma
GlaxoSmithKline may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union. 23 January 2020
Europe
A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties. 23 January 2020
Americas
A life sciences litigator from Williams & Connolly has joined Latham & Watkins’ Washington, DC office. 22 January 2020
Big Pharma
Phase one of the US-China trade deal agreed last week is a major win for pharmaceutical companies, lawyers have told LSIPR. 21 January 2020
Medtech
The US Patent and Trademark Office has denied an inter partes review petition from Edwards Lifesciences, which argued that certain claims relating to Abbott’s MitraClip mitral valve repair device are unpatentable. 21 January 2020
Americas
A US judge has thrown out a lawsuit accusing US biotechnology companies Illumina and Affymetrix of a “complex, multi-decade concerted effort” to conceal the theft of trade secrets in the 1990s. 17 January 2020
Big Pharma
Global healthcare provider Eli Lilly has agreed to buy Dermira, a biopharmaceutical company, for $1.1 billion, giving it access to a late-stage atopic dermatitis drug and allowing it to challenge Sanofi’s already fully-licenced dupilumab. 16 January 2020